DRMA Latest News, Press Relases and Analysis

All

Press Releases

41 minutes ago - By: ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: SNWV CLRB APVO SPRB ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

3 months ago - By: The Motley Fool

Dermata Posts Narrower Loss in Q2

3 months ago - By: ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: SNWV ONMD GLMD APVO ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

a month ago - By: ACCESS Newswire

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

7 months ago - By: ACCESS Newswire

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

8 months ago - By: ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

2 months ago - By: Virtual Investor Conferences - Mentions: KLYG UEEC PETV HEM.CA ...

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

2 months ago - By: ACCESS Newswire

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

2 months ago - By: Virtual Investor Conferences - Mentions: UEEC KLYG PETV HEM.CA ...

Life Science Virtual Investor Forum Agenda Announced for September 18th

10 months ago - By: ACCESS Newswire

Dermata to Present on BioPub on January 31, 2025

2 months ago - By: Virtual Investor Conferences

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

2 months ago - By: ACCESS Newswire

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

4 months ago - By: ACCESS Newswire

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

6 months ago - By: ACCESS Newswire

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

8 months ago - By: ACCESS Newswire

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

9 months ago - By: Dermata Therapeutics, Inc.

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

9 months ago - By: ACCESS Newswire

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

10 months ago - By: ACCESS Newswire

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

10 months ago - By: ACCESS Newswire

DERMATA THERAPEUTICS INC (DRMA) Stock News

DRMA Latest News, Press Relases and Analysis

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

12 Health Care Stocks Moving In Tuesday's Intraday Session

Dermata Posts Narrower Loss in Q2

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Life Science Virtual Investor Forum Agenda Announced for September 18th

Dermata to Present on BioPub on January 31, 2025

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)